Document is current
Any future updates will be listed below
-
Authors
Shang, Ya-xi
Dong, Xia
Xie, Zhi-min
Li, Xiao-peng
Wang, Xin-chang
Huang, Ji-yong
Wei, Shu-feng
Liu, Yuan
Liu, Jian-ping
-
Funding
Funding for this research was provided by:
tibet cheezheng tibetan medicine co., ltd. (not applicable)
Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202006)
Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202006)
Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines (2180072120104)
Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines (2180072120104)
- License Information
-
More Information
Article History
Received: 11 July 2021
Accepted: 23 April 2022
First Online: 12 May 2022
Declarations
:
: This study has obtained the ethics approval from the Ethics Committee of Fangshan Hospital, Beijing University of Chinese Medicine on September 18, 2020 (Reference No. FZY LK-2020-015); from the Ethics Committee of The Second Affiliated Hospital of Zhejiang Chinese Medical University on January 26, 2021 (Reference No. 2020-Y-003-IH01); and from the Ethics Committee of Liuzhou People’s Hospital on April 26, 2021 (Reference No. GCP2021-015-01). Before participating, all participants will be fully informed of the trial and sign an informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
